Atlas Trials

The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation

Clinical trial NCT06561880 · RECRUITING

Trial details

NCT number
NCT06561880
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
FLT3 Gene MutationAML
Start date
2024-10-08
Primary completion
2026-09-01
Enrollment
66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.